Publications by authors named "Danilo Giffoni de Mello Morais Mata"
Article Synopsis
- An analysis of chemotherapy treatments for high-risk early breast cancer compared the standard anthracycline-taxane regimen with the alternative docetaxel and cyclophosphamide (TC).
- The study reviewed data from seven randomized-controlled trials involving nearly 12,000 patients, focusing on disease-free survival (DFS), overall survival (OS), and cardiotoxicity.
- Results showed no significant differences in DFS, OS, or cardiotoxicity between TC and anthracycline-taxane, except for patients with four or more lymph nodes, who benefited more from the anthracycline-taxane treatment.
Background: The overexpression of the human epidermal growth factor receptor 2 (HER2+) accounts for 15-20% of all breast cancer phenotypes. Even after the completion of the standard combination of chemotherapy and trastuzumab, relapse events occur in approximately 15% of cases. The neoadjuvant approach has multiple benefits that include the potential to downgrade staging and convert previously unresectable tumors to operable tumors.
View Article and Find Full Text PDFPurpose Of The Review: The aim of this review is to describe the clinical use and tolerability of immune checkpoint inhibitors in older adults with solid tumors, where there is an abundance of evidence with recent updates including subgroups of older patients.
Recent Findings: Studies with updated analyses and subgroups of older patients show that in general older patients benefit as well as younger patients and tolerate immunotherapy very well. However, in some instances of combination therapies which may expose patients to more toxicity, the benefits are reduced, and careful selection of older patients, including adjunctive assessments such as geriatric assessment, can help to identify the appropriate treatment for an individual patient.
Background: Approximately 75% of breast cancer (BC) is associated with luminal differentiation expressing endocrine receptors (ER). For ER+ HER2- tumors, adjuvant endocrine therapy (ET) is the cornerstone treatment. Although relapse events steadily continue, the ET benefits translate to dramatically lengthen life expectancy with bearable side-effects.
View Article and Find Full Text PDFPredicting treatment toxicity in older adults with cancer.
Curr Opin Support Palliat Care
March 2021
Purpose Of Review: To provide an overview of the recent advancements in predicting toxicity associated with cancer treatment in older patients.
Recent Findings: Various screening tools and validated risk calculators have been shown to help predict toxicity from surgery and chemotherapy. Radiation therapy has been more challenging to select the appropriate tool to reliably predict patients at risk for toxicity and noncompliance.